Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
mRNA Cancer Vaccines And Therapeutics Market Growth From $82.67 Billion In 2026 To $141.51 Billion By 2030 At A CAGR Of 14.4%
In recent years, the mrna cancer vaccines and therapeutics market has experienced substantial growth in its size. It will grow from $71.22 billion in 2025 to $82.67 billion in 2026 at a compound annual growth rate (CAGR) of 16.1%. This historical expansion can be attributed to factors such as the successful application of mrna platforms in infectious disease vaccines, progress in cancer immunology research, an enhanced understanding of tumor antigens, the early clinical validation of mrna cancer therapies, and increased public and private sector funding directed towards oncology innovation.
The mrna cancer vaccines and therapeutics market is projected to experience substantial expansion over the coming years. Its valuation is set to reach $141.51 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 14.4%. This anticipated growth throughout the forecast period stems from factors such as an escalating global cancer burden, the increasing need for personalized and targeted cancer therapies, the expansion of mrna manufacturing capabilities, a rise in oncology clinical trials leveraging mrna platforms, and strategic alliances formed between biotechnology and pharmaceutical firms. Key trends anticipated during this period encompass a greater adoption of personalized cancer vaccines, the broadening of mrna-based therapeutics beyond oncology applications, an intensified focus on developing neoantigen-specific vaccines, an expanding clinical pipeline for mrna cancer immunotherapies, and increased capital allocation towards scalable mrna manufacturing platforms.
Get A Free Sample Report With In-Depth Market Insights:
mRNA Cancer Vaccines And Therapeutics Market Growth Momentum: What Factors Are Shaping Demand?
The growing incidence of cancer is anticipated to drive the expansion of the mRNA cancer vaccine and therapeutic market. Cancer encompasses a range of diseases marked by the uncontrolled proliferation and spread of atypical cells capable of invading and damaging healthy bodily tissues. The rising frequency of cancer cases is largely attributed to elements such as inactive lifestyles, poor dietary choices, and exposure to environmental toxins, all of which elevate the risk of developing diverse malignancies. mRNA cancer vaccines and therapeutics are pivotal in advancing cancer treatment by facilitating personalized, precise immune responses that assist the body in identifying and eliminating cancer cells more efficiently, thus improving therapeutic outcomes. For example, in January 2024, according to the American Cancer Society, Inc., a US-based cancer advocacy organization, it was predicted that the United States would see over 611,000 cancer-related deaths in 2024, which averages out to more than 1,600 fatalities daily. Hence, the increasing prevalence of cancer is propelling the growth of the mRNA cancer vaccine and therapeutic market.
mRNA Cancer Vaccines And Therapeutics Market Segment Breakdown: Which Categories Lead On Revenue?
The mrna cancer vaccines and therapeutics market covered in this report is segmented –
1) By Type: Adeno Carcinomas, Mucinous Carcinomas, Adenosquamous Carcinomas
2) By Application: Cancer, Other Applications
3) By End User: Hospitals And Clinics, Ambulatory Surgical Centers, Research Institutes, Other End Users
Subsegments:
1) By Adeno Carcinomas: Lung Adenocarcinomas, Colon Adenocarcinomas, Prostate Adenocarcinomas
2) By Mucinous Carcinomas: Mucinous Ovarian Cancer, Mucinous Breast Cancer, Mucinous Colorectal Cancer
3) By Adenosquamous Carcinomas: Pancreatic Adenosquamous Carcinoma, Cervical Adenosquamous Carcinoma, Esophageal Adenosquamous Carcinoma
mRNA Cancer Vaccines And Therapeutics Market Trends Redefining Industry Growth
Key companies within the mRNA cancer vaccines and therapeutics market are focusing on developing innovative solutions, such as personalized neoantigen vaccines, to improve immune responses and patient survival outcomes in cancer. Personalized neoantigen vaccines are cancer treatments designed specifically for each patient, utilizing unique tumor-specific mutations to stimulate the immune system to target and destroy cancer cells. For example, in July 2023, Merck & Co., Inc., a US-based research-intensive biopharmaceutical company, partnered with Moderna Therapeutics, Inc., a US-based biotechnology company, to initiate a Phase 3 randomized clinical trial (V940-001). This trial will evaluate mRNA-4157 (V940) in combination with KEYTRUDA (pembrolizumab) as an adjuvant therapy for patients with resected high-risk (Stage IIB-IV) melanoma. This study follows positive results from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial, which indicated a meaningful benefit of the combination over KEYTRUDA alone in reducing the risk of recurrence and distant metastasis. The Phase 3 trial seeks to confirm these findings by assessing relapse-free survival and distant metastasis-free survival as its primary and secondary endpoints, respectively.
mRNA Cancer Vaccines And Therapeutics Market Leading Players And Competitive Positioning
Major companies operating in the mrna cancer vaccines and therapeutics market are BioNTech SE, Moderna Therapeutics Inc., CureVac N.V., Arcturus Therapeutics Holdings Inc., Immatics Biotechnologies GmbH, Argos Therapeutics Inc., Anima Biotech, Translate Bio, eTheRNA Immunotherapies NV, Gritstone bio Inc., Neon Therapeutics, Codiak BioSciences, Cartesian Therapeutics, Replimune Group Inc., Precision BioSciences, Acuitas Therapeutics, Ethris GmbH, Strand Therapeutics, Crown Bioscience, Roche (Hoffmann-La Roche AG)
View The Full mRNA Cancer Vaccines And Therapeutics Market Report:
mRNA Cancer Vaccines And Therapeutics Market Geographic Analysis: Where Is Demand Rising Fastest?
North America was the largest region in the mRNA cancer vaccination and therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mrna cancer vaccines and therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
